The challenge of defining metabolic dysfunction and alcohol-associated liver disease - PubMed
3 hours ago
- #metabolic dysfunction
- #conflict of interest
- #liver disease
- The article discusses the challenge of defining metabolic dysfunction and alcohol-associated liver disease.
- Multiple authors have disclosed conflicts of interest, including consulting roles, speaker engagements, and research grants from pharmaceutical companies.
- Key pharmaceutical companies involved include AstraZeneca, Gilead Sciences, Novo Nordisk, and Boehringer Ingelheim.
- Some authors have stock options or are co-founders of biotech firms, indicating potential financial interests in the discussed topics.